Arctic Vision develops gene and cell therapies for various ophthalmic conditions, including glaucoma, inherited retinal degeneration, and corneal endothelial dysfunction, utilizing advanced delivery methods such as AAV-based systems and suprachoroidal space injections. Their therapies aim to improve patient outcomes by addressing the limitations of current treatments, such as the inefficiency of cornea transplants and the need for new mechanisms to prevent vision loss.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LVFounders
Product
Problem
Current treatments for ophthalmic conditions like glaucoma, inherited retinal degeneration, and corneal endothelial dysfunction often have limitations, such as the invasiveness and inefficiency of cornea transplants or the lack of effective mechanisms to prevent vision loss in progressive diseases. Traditional delivery methods may also limit the efficacy and accessibility of therapies.
Solution
Arctic Vision is a biopharmaceutical company focused on developing and commercializing innovative gene and cell therapies to address unmet needs in ophthalmology. The company utilizes advanced delivery technologies, including AAV-based gene therapy and suprachoroidal space (SCS) injection, to target a range of ophthalmic diseases. Their pipeline includes therapies for glaucoma, inherited retinal degeneration, corneal endothelial dysfunction, uveitic macular edema (UME), diabetic macular edema (DME), retinopathy, myopia, and presbyopia. Arctic Vision aims to improve patient outcomes by providing more effective and less invasive treatment options for vision-threatening conditions.
Target Audience
Arctic Vision's therapies target patients suffering from glaucoma, inherited retinal degeneration, corneal endothelial dysfunction, uveitic macular edema, diabetic macular edema, retinopathy, myopia, presbyopia, and dry eye disease.
Features
- ARVN601: MicroRNA-based neuroprotective gene therapy for glaucoma.
- ARVN602 & ARVN603: Gene therapy for inherited retinal degeneration utilizing AAV-based delivery.
- ARVN901: Cell therapy for corneal endothelial dysfunction designed to increase cornea donor use efficiency.
- ARCATUS® (ARVN001): Triamcinolone acetonide injectable suspension for UME and DME, delivered via suprachoroidal space (SCS) injection.
- ARVN006: Small molecule product targeting retinopathy.
- ARVN004: Micro-array print formulation for mydriasis.
- ARVN002: Micro-array print formulation for myopia.
- ARVN003: Micro-array print formulation for presbyopia.
- iTEAR® (ARVN701): Extranasal neurostimulation device for dry eye treatment.
- ARVN 8 Series: Consumer eye care products.